Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 25819666 | HLA-A*03 | prostate cancer | NA | NA | NA | unclassified | |
| five ezh2-derived peptides that were prepared based on the binding motif to the hla-a3 supertype alleles (hla-a11, -a31, and -a33) were functionally screened for their potential to induce peptide-specific ctls from peripheral blood mononuclear cells (pbmcs) of hla-a3 supertype allele(+) prostate cancer patients. | |||||||
| 25819666 | HLA-A*03 | prostate cancer | NA | NA | NA | unclassified | |
| the ezh2733-741 peptide-stimulated and purified cd8(+) t cells from pbmcs of hla-a3 supertype allele(+) prostate cancer patients showed higher cytotoxicity against hla-a3 supertype allele-expressing lncap prostate cancer cells than against parental lncap cells. | |||||||
| 25819666 | HLA-A*03 | prostate cancer | NA | NA | NA | unclassified | |
| these results indicate that the ezh2733-741 peptide could be a promising candidate for peptide-based immunotherapy for hla-a3 supertype allele(+) prostate cancer patients. | |||||||
| 27891225 | MHC (MHC) | prostate cancer | NA | NA | NA | unclassified | |
| we analyzed prostate cancer patients who were vaccinated with the ae37 vaccine [ii-key-her-2/neu(776-790) hybrid peptide vaccine (ae37), which is a mhc class ii long peptide vaccine encompassing mhc class i epitopes, during a phase i clinical trial. | |||||||
| 33200227 | HLA-A*24 | prostate cancer | NA | docetaxel | NA | unclassified | |
| to develop a new treatment modality, we conducted a phase iii randomized trial of personalized peptide vaccination (ppv) for human leukocyte antigen (hla)-a24-positive patients with castration-resistant prostate cancer (crpc) for whom docetaxel chemotherapy failed. | |||||||
| 33200227 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | prostate cancer | NA | docetaxel | NA | unclassified | |
| to develop a new treatment modality, we conducted a phase iii randomized trial of personalized peptide vaccination (ppv) for human leukocyte antigen (hla)-a24-positive patients with castration-resistant prostate cancer (crpc) for whom docetaxel chemotherapy failed. | |||||||
| 33976942 | HLA-DPA1 (HLA-DPA1) | prostate cancer | Arabian | NA | rs3077 | unclassified | |
| the weight of hla-dpa1 rs3077 single nucleotide polymorphism in prostate cancer, a multicenter study. | |||||||
| 33976942 | HLA-DPA1 (HLA-DPA1) | prostate cancer | Arabian | NA | rs3077 | unclassified | |
| hla-dpa1 rs3077 g allele could be a risk factor for prostate cancer. | |||||||
| 33976942 | HLA-DPA1 (HLA-DPA1) | prostate cancers | Arabian | NA | rs3077 | unclassified | |
| to determine the relevance of hla-dpa1 rs3077 (a/g) snp with prostate cancer's risk and/or severity. | |||||||
| 9051144 | HLA-A*02 | prostate cancers | NA | NA | NA | unclassified | |
| a large portion of patients with prostate cancer express the hla-a2 phenotype, implying that many prostate cancers might be targeted by hla-a2-restricted ctl with specificity for the psa 146-154 epitope. | |||||||
Copyright 2024